Skip to content
OpenCapital
Get started

Boston Scientific BSX Legal payments remaining to be excluded from calculation of consolidated EBITDA

Other financials

Income statement

See full
Revenue$5.2B+11.6%
Gross profit$3.6B+12.6%
Operating income$1.1B+19.5%
Net income$1.3B+99.3%
EPS (diluted)$0.90+100%

Balance sheet

See full
Cash & equivalents$850.0M+146%
Total equity$25.9B+16.4%
Total assets$44.4B+10.5%

Cash flow

See full
Operating cash flow$348.0M-35.7%
CapEx$177.0M-5.4%
Free cash flow$171.0M-51.7%

Valuation

See full
Market cap$67.32B-37.5%
P/E18.9×-34.3×
P/S3.3×-2.9×

Profitability

See full
Gross margin69.2%+0.5pp
Operating margin18.4%+2.2pp
Net margin17.3%+5.7pp

Returns & leverage

See full
Return on equity14.8%+5.2pp
Debt / equity0×-0.5×
Current ratio1.9×+0.4×

Where this comes from

Reported directly by Boston Scientific in its filing.

Tagged under the XBRL concept bsx:LegalPaymentsRemainingToBeExcludedFromCalculationOfConsolidatedEbitda.

The official record: Boston Scientific’s 10-Q, filed May 1, 2026, on SEC EDGAR. View the filing →

Ask your AI about Boston Scientific's legal payments remaining to be excluded from calculation of consolidated ebitda.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Boston Scientific's legal payments remaining to be excluded from calculation of consolidated EBITDA?
Boston Scientific (BSX) reported legal payments remaining to be excluded from calculation of consolidated EBITDA of $1.14B in Q1 2026.
How has Boston Scientific's legal payments remaining to be excluded from calculation of consolidated EBITDA changed year-over-year?
Boston Scientific's legal payments remaining to be excluded from calculation of consolidated EBITDA decreased by 20.0% year-over-year, from $1.43B to $1.14B.